You are here

FDA Approves Tolsura for Systemic Fungal Infections

New Antifungal Has Increased Bioavailability and Reduced Variability

The FDA has approved the new drug application for Tolsura (SUBA-itraconazole, Mayne Pharma). SUBA-itraconazole is indicated for the treatment of certain systemic fungal infections in adult patients.

The new formulation of traconazole is indicated for the treatment of blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or refractory to amphotericin B therapy.

These serious infections most commonly occur in vulnerable or immunocompromised patients, for example, those with a history of cancer, transplants, HIV/AIDS, or chronic rheumatic disorders.

Among the most common adverse reactions are nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, and hypertension.

SUBA-itraconazole 65-mg tablets are expected to be available in January 2019.

Sources: Specialty Pharmacy Times, December 13, 2018; Drugs.com, December 11, 2018

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time